BioNTech (BNTX) - 22.18% Below 52-Week High: Buy or Wait?

Stock Details

BioNTech SE (BNTX), a prominent company in the healthcare sector within the biotechnology industry, is based in Germany and primarily trades on the NMS.Currently, the stock is trading at $96.50. Over the past 52 weeks, it has ranged between $79.52 and $124.00. This places the current price at 77.8% of its 52-week high and 21.4% above its 52-week low. Recent trading volume was recorded at 899,377. The 14-day Relative Strength Index (RSI) stands at 43.01, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $98.69 by 2.22%. Similarly, it is below its 200-day moving average of $97.75 by 1.28%. The MACD histogram is -0.26, indicating bearish momentum (MACD Line: -0.74, Signal Line: -0.48). There are currently 2 active alerts set for BNTX by users.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-17.37

PEG Ratio

0.05

Potentially undervalued

Price to Book

1.21

EV/EBITDA

-7.89

EPS (TTM)

-$7.67

Price to Sales

9.07

Beta

1.25

Similar volatility to market

Q:How is BNTX valued relative to its earnings and growth?

Valuation data is not available for this stock.

Q:What is BNTX's risk profile compared to the market?

With a beta of 1.25, BioNTech SE is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 1.21 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-63.64%

Operating Margin

-806.63%

EBITDA

$-1,380,800,000

Return on Equity

-9.30%

Return on Assets

-5.41%

Revenue Growth (YoY)

-59.50%

Q:How profitable and efficient is BNTX's business model?

BioNTech SE achieves a profit margin of -63.64%, meaning it retains $-63.64 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -806.63% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -9.30% and ROA at -5.41%, the company achieves moderate returns on invested capital.

Q:What are BNTX's recent growth trends?

BioNTech SE's revenue declined by 59.50% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$24.0B

Revenue (TTM)

$2.65B

Revenue/Share (TTM)

$10.69

Shares Outstanding

251.20M

Book Value/Share

$79.29

Asset Type

EQUITY

Q:What is BNTX's market capitalization and position?

BioNTech SE has a market capitalization of $24.0B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 251.20M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.

Q:How does BNTX's price compare to its book value?

BioNTech SE's book value per share is $79.29, while the current stock price is $96.50, resulting in a price-to-book (P/B) ratio of 1.22. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$116.07

20.28% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for BNTX?

20 analysts cover BNTX with 75% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $116.07 implies 20.3% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on BNTX?

Current analyst recommendations:1 Strong Buy, 14 Buy, 4 Hold, 01 Strong Sell. The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 7, 2026, 02:06 AM

Technical Indicators

RSI (14-day)

43.01

Neutral

50-Day Moving Average

$98.69

-2.22% below MA-50

200-Day Moving Average

$97.75

-1.28% below MA-200

MACD Line

-0.74

MACD Signal

-0.48

MACD Histogram

-0.26

Bearish

Q:What does BNTX's RSI value tell investors?

The RSI (Relative Strength Index) for BNTX is currently 43.01, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.

Q:How should traders interpret BNTX's MACD and moving average crossovers?

MACD analysis shows the MACD line at -0.74 below the signal line at -0.48, with histogram at -0.26. This bearish crossover indicates downward pressure. The 50-day MA ($98.69) is above the 200-day MA ($97.75), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently below both MAs, confirming weakness.

Indicators last updated: Oct 7, 2026, 01:18 AM

Condition	Threshold	Created At
Price falls below	$92.00	Oct 6, 2026, 04:17 PM
Price rises above	$104.58	Oct 6, 2026, 04:17 PM

Condition

Threshold

Created At

Price falls below

$92.00

Oct 6, 2026, 04:17 PM

Price rises above

$104.58